Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Clinical trial NCT05990920 · COMPLETED

Trial details

NCT number: NCT05990920
Sponsor: NKGen Biotech, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pathologically Confirmed Cancer Refractory to Conventional Therapy Refractory Cancer Metastatic Cancer Recurrent Cancer Solid Tumor, Adult Solid Tumor Advanced Cancer Advanced Solid Tumor

Start date: 2023-08-23
Primary completion: 2024-04-12
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.